Brief: Xbiotech Announces First Subject Enrollment In Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke
17/04/2023 14:02
April 17 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH ANNOUNCES FIRST SUBJECT ENROLLMENT IN PHASE I
CLINICAL
TRIAL FOR HUTRUKIN, A NOVEL CANDIDATE THERAPY FOR STROKE
* XBIOTECH ANNOUNCES FIRST SUBJECT ENROLLMENT IN PHASE I
CLINICAL
TRIAL FOR HUTRUKIN, A NOVEL CANDIDATE THERAPY FOR STROKE
Source text for Eikon: ID:nGNX9BMdBw
Further company coverage: XBIT.O
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke